Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01893398
Other study ID # FdG_AD_01
Secondary ID
Status Completed
Phase N/A
First received June 24, 2013
Last updated July 2, 2013
Start date January 2010

Study information

Verified date June 2013
Source Fondazione Don Carlo Gnocchi Onlus
Contact n/a
Is FDA regulated No
Health authority Italy: Ministry of Health
Study type Interventional

Clinical Trial Summary

Our previous findings support the notion that group activity program, based on cognitive stimulation, recreational-occupational activities and physical-psychomotor exercises, can lead to an improvement in behavioral aspects for people with Alzheimer's Disease (AD).

The purpose of this study is to clarify the efficacy of a rehabilitation program in outpatients affected by AD in mild to moderate stages.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 65 Years to 85 Years
Eligibility Inclusion Criteria:

- diagnosis of possible/probable AD

- mild to moderate stage of AD (MMSE score of 15 - 24)and CDR score of 1-2

- range years in age (65-85) and in school attendance (5-17)

- right handed

Exclusion Criteria:

- severe aphasia (Token test score < 20)

- severe auditory and/or visual loss

- overt severe behavioral disturbances (delusions, hallucinations, agitation)

- recent (three month before the MST) introduction or dose modification of the following pharmacological treatments: cholinesterase inhibitor, memantine, antidepressant or antipsychotic drugs.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)


Related Conditions & MeSH terms


Intervention

Other:
Multidimensional stimulation group therapy
The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.

Locations

Country Name City State
Italy IRCCS, S Maria Nascente, FOndazione don Gnocchi Milan

Sponsors (1)

Lead Sponsor Collaborator
Fondazione Don Carlo Gnocchi Onlus

Country where clinical trial is conducted

Italy, 

References & Publications (2)

Farina E, Fioravanti R, Chiavari L, Imbornone E, Alberoni M, Pomati S, Pinardi G, Pignatti R, Mariani C. Comparing two programs of cognitive training in Alzheimer's disease: a pilot study. Acta Neurol Scand. 2002 May;105(5):365-71. — View Citation

Farina E, Mantovani F, Fioravanti R, Pignatti R, Chiavari L, Imbornone E, Olivotto F, Alberoni M, Mariani C, Nemni R. Evaluating two group programmes of cognitive training in mild-to-moderate AD: is there any difference between a 'global' stimulation and a 'cognitive-specific' one? Aging Ment Health. 2006 May;10(3):211-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Functional MRI Change from baseline in brain functioning. We used fMRI with cognitive task to detect possible changes (10 ws versus baseline) in brain activation patterns in PWA as a surrogate biomarker of efficacy. baseline, 10 ws No
Primary Change from baseline in behavioral level Neuropsychiatric Inventory scale Baseline, 10ws, 22ws No
Primary Change from baseline in cognitive level ADAS cog scale Baseline, 10ws, 22 ws No
Primary Change from baseline in quality of life SF36 questionaire baseline, 10ws,22 ws No
See also
  Status Clinical Trial Phase
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Recruiting NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease Phase 2
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease N/A
Active, not recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Completed NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Completed NCT02260167 - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol N/A
Withdrawn NCT01636596 - Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease N/A

External Links